dalteparin
Selected indexed studies
- Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. (J Thromb Haemost, 2020) [PMID:31630479]
- Dalteparin: a low-molecular-weight heparin. (Ann Pharmacother, 1997) [PMID:9034422]
- Dalteparin sodium. (Expert Opin Pharmacother, 2001) [PMID:11585001]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. (2020) pubmed
- Dalteparin: a low-molecular-weight heparin. (1997) pubmed
- Dalteparin sodium. (2001) pubmed
- Dalteparin: an update of its pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic disease. (2000) pubmed
- Dalteparin sodium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. (1996) pubmed
- Obstetric venous thromboembolism: a systematic review of dalteparin and pregnancy. (2019) pubmed
- Dalteparin: pharmacological properties and clinical efficacy in the prophylaxis and treatment of thromboembolic diseases. (2004) pubmed
- Efficacy and Safety of Apixaban versus Dalteparin as a Treatment for Cancer-Associated Venous Thromboembolism: A Systematic Review and Meta-Analysis. (2023) pubmed
- Dalteparin in Newborn Thrombosis, Time for a New Starting Dose. (2021) pubmed
- Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism: A Randomized Trial. (2022) pubmed